Stay updated on Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial
Sign up to get notified when there's something new on the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page.

Latest updates to the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedSite revision updated from v3.4.1 to v3.4.2 with no observable changes to study content or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check20 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; no user-facing content or functionality on the Study Details page appears to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedUI updates include a Show glossary option and a new revision tag (v3.4.0). Minor label/capitalization changes were made to items like No FEAR Act Data and Last Update Submitted that Met QC Criteria, replacing older variants.SummaryDifference0.2%

- Check42 days agoChange DetectedSite revision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded a dedicated Locations section listing California, Massachusetts, New Jersey, New York, and Pennsylvania; updated the page revision to v3.3.3 and removed the HHS Vulnerability Disclosure and the individual state location entries.SummaryDifference0.5%

- Check91 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no study content or site functionality has changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page.